ENGINEERED PROTEINS TO REPAIR OR REGROW DAMAGED HEART MUSCLE CELLS AND TISSUE
Associate Professor Dan Hesselson,
Head of the Centre for Biomedical AI,
Centenary Institute
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | July 2026
Associate Professor Dan Hesselson leads the Centre for Biomedical AI at the Centenary Institute.
He is an internationally trained research leader in regenerative medicine, focusing on cells and organs affected by heart disease, diabetes and cancer. His work uses insights from the study of basic regenerative processes to identify novel therapeutic targets for these devastating diseases.
His work with zebrafish, which started at University of California San Francisco (UCSF) and was expanded at the Garvan Institute, made significant contributions to our understanding of the molecular mechanisms of regeneration in this highly regenerative model system.
At the Centenary Institute, he is focused on exploiting these breakthroughs in basic science to develop new therapeutic strategies using the power of Directed Evolution to generate potent and highly specific biologic drugs.
His research is investigating new ways to repair the heart and improve outcomes for individuals recovering from heart attacks or living with heart disease, aiming to address a critical gap in cardiac care.
While current treatments can manage symptoms, they cannot restore heart function once muscle cells are lost. This irreversible damage is why heart failure remains a leading cause of death worldwide.
Associate Professor Hesselson’s research aims to address this challenge by developing therapies based on engineered proteins capable of repairing or regrowing damaged heart muscle cells and tissue.
Source: Supplied and adapted from Centenary Institute media release (June 2026)
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
-
Role of Community Paramedicine in Non-Emergency Presentations
Dr Robbie King is a Lecturer in paramedicine and researcher at the Australian Catholic University (ACU) Brisbane. He also continues to provide clinical care as a registered paramedic for community members served by a jurisdictional ambulance service. Dr King has gained significant experience working in an advanced practice, community paramedic style role, holding expert clinical insight into the nuances of paramedic-led community-based healthcare for non-emergency presentations. This often involves adopting a biopsychosocial approach, rather than following the biomedical model more associated with emergency medicine and paramedic culture.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
